BioLife Solutions’ (BLFS) Buy Rating Reiterated at Benchmark

Benchmark reaffirmed their buy rating on shares of BioLife Solutions (NASDAQ:BLFS) in a research note issued to investors on Thursday morning,Benzinga reports. Benchmark currently has a $30.00 price target on the medical equipment provider’s stock.

Several other analysts have also recently commented on BLFS. KeyCorp raised their price target on BioLife Solutions from $30.00 to $33.00 and gave the company an “overweight” rating in a report on Friday, December 13th. HC Wainwright decreased their target price on shares of BioLife Solutions from $29.00 to $27.00 and set a “buy” rating on the stock in a research report on Monday, November 18th. Craig Hallum increased their price target on shares of BioLife Solutions from $30.00 to $32.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Finally, TD Cowen boosted their price objective on shares of BioLife Solutions from $28.00 to $31.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $29.00.

BioLife Solutions Trading Up 4.9 %

NASDAQ BLFS opened at $27.39 on Thursday. The company has a quick ratio of 1.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.03. The stock has a market capitalization of $1.27 billion, a P/E ratio of -25.84 and a beta of 1.91. BioLife Solutions has a 52-week low of $14.50 and a 52-week high of $28.88. The firm has a 50-day moving average price of $24.96 and a 200 day moving average price of $23.72.

Insider Buying and Selling at BioLife Solutions

In other news, EVP Aby J. Mathew sold 7,604 shares of the stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $27.33, for a total value of $207,817.32. Following the sale, the executive vice president now directly owns 276,315 shares in the company, valued at $7,551,688.95. This represents a 2.68 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In the last three months, insiders sold 64,259 shares of company stock worth $1,424,708. 2.20% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On BioLife Solutions

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Principal Financial Group Inc. increased its position in BioLife Solutions by 4.7% during the third quarter. Principal Financial Group Inc. now owns 190,715 shares of the medical equipment provider’s stock worth $4,776,000 after buying an additional 8,580 shares in the last quarter. Barclays PLC increased its position in BioLife Solutions by 20.1% during the 3rd quarter. Barclays PLC now owns 64,423 shares of the medical equipment provider’s stock worth $1,613,000 after purchasing an additional 10,803 shares in the last quarter. Geode Capital Management LLC raised its stake in BioLife Solutions by 2.2% in the 3rd quarter. Geode Capital Management LLC now owns 842,771 shares of the medical equipment provider’s stock valued at $21,107,000 after purchasing an additional 18,473 shares during the last quarter. State Street Corp lifted its holdings in BioLife Solutions by 7.3% in the 3rd quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider’s stock valued at $35,364,000 after purchasing an additional 95,788 shares in the last quarter. Finally, Stifel Financial Corp boosted its stake in shares of BioLife Solutions by 5.4% during the 3rd quarter. Stifel Financial Corp now owns 12,988 shares of the medical equipment provider’s stock worth $325,000 after purchasing an additional 670 shares during the last quarter. Hedge funds and other institutional investors own 93.24% of the company’s stock.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.